ISG Technologies postponed the release of its year-end financialresults this month, citing a lawsuit filed against the Mississauga,Ontario, PACS developer by its former president and CEO ThomasCafarella. ISG said it needs time to determine whether it
ISG Technologies postponed the release of its year-end financialresults this month, citing a lawsuit filed against the Mississauga,Ontario, PACS developer by its former president and CEO ThomasCafarella. ISG said it needs time to determine whether it shouldtake a charge as a provision for the litigation.
Cafarella filed suit against ISG last month, charging the companywith breach of contract when it dismissed him on Aug. 8 (SCAN8/28/96). Cafarella is claiming damages of $1.5 million (Canadian).
In addition to Cafarella, two other executives associated withthe former Siemens executive have left ISG. They are Denis O'Connor,a Loral veteran who was vice president of sales and marketing,and Gary Hepworth, director of human resources. Both had beenhired by Cafarella, according to ISG's CFO, Gerry McDonald.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.